Cevoglitazar
Cevoglitazar (LBM-642) is an orally active and highly potent PPARα and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research[1].
Product Specifications
CAS Number
839673-52-8
Product Name Alternative
LBM-642
UNSPSC
12352005
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/cevoglitazar.html
Smiles
O=C([C@@H]1N(S(=O)(C2=CC=C(OCC3=C(C)OC(C4=CC=C(C(F)(F)F)C=C4)=N3)C=C2)=O)C5=C(C=CC=C5)C1)O
Molecular Formula
C27H21F3N2O6S
Molecular Weight
558.53
References & Citations
[1]Hong Chen, et al. Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys. Endocrinology. 2010 Jul;151 (7) :3115-24.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PPARα; PPARγ
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
